4.6 Article

Decreased Management of Genital Warts in Young Women in Australian General Practice Post Introduction of National HPV Vaccination Program: Results from a Nationally Representative Cross-Sectional General Practice Study

Journal

PLOS ONE
Volume 9, Issue 9, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0105967

Keywords

-

Funding

  1. Australian Government Department of Health and Ageing
  2. Australian Government Department of Veterans' Affairs
  3. Australian Institute of Health and Welfare
  4. National Prescribing Service
  5. AstraZeneca Pty Ltd (Australia)
  6. Janssen-Cilag Pty Ltd
  7. Merck
  8. Sharpe and Dohme (Australia) Pty Ltd
  9. Pfizer Australia Pty Ltd
  10. Abbott Australasia Pty Ltd
  11. Sanofi-Aventis Australia Pty Ltd
  12. Wyeth Australia Pty Ltd
  13. Novartis Pharmaceuticals Australia Pty Ltd
  14. GlaxoSmithKline Australia Pty Ltd
  15. Roche Products Pty Ltd
  16. BioCSL Pty Ltd
  17. Bayer Australia Ltd

Ask authors/readers for more resources

Objectives: Since the introduction of Australia's human papillomavirus vaccination program, the management rate of genital warts in sexual health clinics and private hospitals has decreased in women of vaccine-eligible age. However, most genital warts in Australia are managed in general practice. This study examines whether a similar decrease occurred in Australian general practice after the introduction of the program. Methods: Analysis of a nationally representative cross-sectional database of Australian general practice activity (1,175,879 patient encounters with 11,780 general practitioners). Genital warts management rates were estimated for the periods before and after introduction of the program (Pre-program, July 2002-June 2006; Post-program, July 2008-June 2012). Control conditions included genital herpes and gardnerella/bacterial vaginosis in female patients and genital herpes and urethritis in male patients. Trends in management rates by year, pre-vaccine (July 2000-June 2007) and post-vaccine (July 2007-June 2012) were also calculated. Results: Management rate of genital warts among women potentially covered by program (aged 15-27 years) decreased by 61% from 4.33 per 1,000 encounters in the Pre-program period to 1.67 in the Post-program period. Trend analysis of the post-vaccine period showed, among women of vaccine eligible age, a significant year-on-year reduction in the rate of genital warts management (p<0.0001) and a significant increase in the management rate of control conditions per year (p<0.0001). For all other age-sex groups there was no significant change in the management rate of genital warts between the Pre-and Post-program periods. Conclusion: The large decrease in general practice management of genital warts in women of vaccine-eligible age highlights the success of the program in the wider community.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available